Digoxin use is associated with pancreatic cancer risk but does not affect survival

Jan-21

Hepatology Oncology Pharmacoepidemiology

AUTHORS : Dr Ben Boursi, Division of Gastroenterology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA / Tel-Aviv University, Tel-Aviv, Israel; Department of Oncology, Sheba Medical Center, Tel-Hashomer, Israel – Email: ben.boursi@sheba.health.gov.il – Profile: https://www.shebaonline.org/doctors/ben-boursi/

JOURNAL : Cancer Causes & Control

REFERENCE: 32(1):41-46

DOI : 10.1007/s10552-020-01352-7

Digoxin use is associated with pancreatic cancer risk but does not affect survival

More publications

Characteristics, risk factors and clinical impact of penicillin and other antibiotic allergies in adults in the UK General Practice: a population-based cohort study

Glucose Lowering through Weight management (GLoW): a randomised controlled trial of the clinical and cost effectiveness of a diabetes education and behavioural weight management programme vs a diabetes education programme in adults with a recent diagnosis of type 2 diabetes

Target Serum Urate Achievement and Chronic Kidney Disease Progression in Patients With Gout and Kidney Disease